Cancer Expenditures and Mortality Trends in Brazil: An Ecological Population-Level Time-Series Analysis, 2008-2023

Brazil has substantially expanded public oncology investment over the past decade, particularly within the Brazilian Unified Health System (SUS). However, whether increased spending has translated into measurable population-level improvements in cancer outcomes remains uncertain.

We conducted a retrospective ecological time-series analysis using national data from 2008 to 2023. Public expenditures for female breast and prostate cancer were extracted from DATASUS and inflation-adjusted, while mortality data were obtained from INCA and age-standardized. Key policy milestones-RDC 55/2010, creation of Conitec in 2011, Ordinance No. 874/2013, and Constitutional Amendment 95/2016-were mapped against expenditure and mortality trends. Findings therefore represent system-level associations rather than causal estimates of patient-level therapeutic effectiveness.

Oncology expenditures increased substantially, with more pronounced growth after 2011, whereas national age-standardized mortality rates for female breast and prostate cancer changed comparatively little. This pattern represents a descriptive temporal divergence between expenditure growth and mortality trends, not evidence of therapeutic inefficacy or a quantified causal effect. Regional differences in diagnostic capacity, healthcare infrastructure, continuity of care, and treatment timeliness may influence how financial inputs translate into population-level outcomes.

Brazil's experience supports a value-oriented oncology strategy linking investment not only to technology incorporation, but also to early diagnosis, implementation capacity, regional equity, and effective care pathways. These ecological findings do not support individual-level causal inference, particularly for prostate cancer, for which mortality is a delayed and relatively insensitive medium-term endpoint. Future studies should incorporate stage at diagnosis, treatment pathways, time-to-treatment indicators, and regional survival data.